Biosplice Therapeutics Announces Initiation of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Trial Sponsored by the National Cancer Institute (NCI)
12 sept. 2024 07h00 HE
|
Biosplice Therapeutics, Inc.
Biosplice Announces Initiation of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Trial Sponsored by the National Cancer Institute (NCI)
Semafore Pharmaceuticals Reports New Preclinical Data for Multi-Kinase, PI3K/mTOR Inhibitor SF1126 at AACR
05 avr. 2011 13h00 HE
|
Semafore Pharmaceuticals
INDIANAPOLIS, April 5, 2011 (GLOBE NEWSWIRE) -- Semafore Pharmaceuticals today announced encouraging preclinical results for its lead product candidate, SF1126, in certain B-cell malignancies. The...
Semafore Pharmaceuticals Announces Presentation Highlighting Activity of Multi-Kinase, PI3K/mTOR Inhibitor SF1126 at 2011 AACR Annual Meeting
09 mars 2011 07h30 HE
|
Semafore Pharmaceuticals
INDIANAPOLIS, March 9, 2011 (GLOBE NEWSWIRE) -- Semafore Pharmaceuticals announced today that preclinical data in B-cell malignancies for the company's lead product candidate SF1126 will be presented...